BioCentury | Oct 1, 2007
Company News

Opexa board of directors update

...The Woodlands, Texas Business: Autoimmune, Gene/Cell therapy Appointed: Lorin Randall, former SVP and CFO of Eximias Pharmaceutical Corp. WIR...
BioCentury | May 29, 2006
Company News

MGI management update

...Business: Cancer Hired: Gerard Kennealey as SVP of clinical development, formerly SVP and CMO at Eximias Pharmaceutical Corp. WIR...
BioCentury | May 15, 2006
Company News

Eximias, YM BioSciences deal

...YM completed its previously announced acquisition of Eximias for US$29 million in stock (see BioCentury, April...
...at US$5.75, which was YMI's close on May 8, the day before the deal completed. Eximias Pharmaceutical Corp....
BioCentury | Apr 17, 2006
Company News

Eximias Phamaceutical Corp., YM BioSciences deal

...YM will acquire Eximias in a stock and cash deal expected to close in early May...
...but did say that Eximias shareholders will receive at least $25 million in YM stock. Eximias...
...cash, will be renamed YM BioSciences USA Inc. and will serve as YM's U.S. headquarters. Eximias...
BioCentury | Apr 14, 2006
Company News

YM acquiring Eximias

...YM (TSX:YM; YMI) said that it will acquire fellow cancer company Eximias (Berwyn, Penn.) in a...
...but did say that Eximias shareholders will receive at least $25 million in YM stock. Eximias...
...will be renamed YM BioSciences USA Inc. and serve as YM's U.S. headquarters. Last August, Eximias'...
BioCentury | Mar 20, 2006
Company News

Acorda board of directors update

...Acorda Therapeutics Inc. (ACOR), Hawthorne, N.Y. Business: Neurology Appointed: Lorin Randall, SVP and CFO at Eximias Pharmaceutical Corp. WIR...
BioCentury | Aug 8, 2005
Clinical News

Thymitaq nolatrexed: Phase III data

...this indication, was licensed from Agouron Pharmaceuticals Inc. (La Jolla, Calif.), a subsidiary of PFE. Eximias Pharmaceutical Corp....
BioCentury | Aug 4, 2005
Clinical News

Eximias' Thymitaq fails HCC Phase III

Eximias (Berwyn, Penn.) said Thymitaq nolatrexed missed the primary endpoint of survival in the Phase III ETHECC trial to treat unresectable hepatocellular carcinoma (HCC). Data from the international, open-label trial in 446 patients were not...
BioCentury | Jul 4, 2005
Finance

Upcoming milestones

...Hypertension Submit MAA 3Q05 Epix/Schering Vasovist (MS-325) Cardiovascular imaging FDA response to NDA in November Eximias/Pfizer...
BioCentury | Jun 13, 2005
Company News

Eximias board of directors update

Eximias Pharmaceutical Corp. , Berwyn, Penn. Business: Cancer Appointed: Ruedi Waeger, former president and CEO of Aventis Behring LLC WIR Staff...
Items per page:
1 - 10 of 44
BioCentury | Oct 1, 2007
Company News

Opexa board of directors update

...The Woodlands, Texas Business: Autoimmune, Gene/Cell therapy Appointed: Lorin Randall, former SVP and CFO of Eximias Pharmaceutical Corp. WIR...
BioCentury | May 29, 2006
Company News

MGI management update

...Business: Cancer Hired: Gerard Kennealey as SVP of clinical development, formerly SVP and CMO at Eximias Pharmaceutical Corp. WIR...
BioCentury | May 15, 2006
Company News

Eximias, YM BioSciences deal

...YM completed its previously announced acquisition of Eximias for US$29 million in stock (see BioCentury, April...
...at US$5.75, which was YMI's close on May 8, the day before the deal completed. Eximias Pharmaceutical Corp....
BioCentury | Apr 17, 2006
Company News

Eximias Phamaceutical Corp., YM BioSciences deal

...YM will acquire Eximias in a stock and cash deal expected to close in early May...
...but did say that Eximias shareholders will receive at least $25 million in YM stock. Eximias...
...cash, will be renamed YM BioSciences USA Inc. and will serve as YM's U.S. headquarters. Eximias...
BioCentury | Apr 14, 2006
Company News

YM acquiring Eximias

...YM (TSX:YM; YMI) said that it will acquire fellow cancer company Eximias (Berwyn, Penn.) in a...
...but did say that Eximias shareholders will receive at least $25 million in YM stock. Eximias...
...will be renamed YM BioSciences USA Inc. and serve as YM's U.S. headquarters. Last August, Eximias'...
BioCentury | Mar 20, 2006
Company News

Acorda board of directors update

...Acorda Therapeutics Inc. (ACOR), Hawthorne, N.Y. Business: Neurology Appointed: Lorin Randall, SVP and CFO at Eximias Pharmaceutical Corp. WIR...
BioCentury | Aug 8, 2005
Clinical News

Thymitaq nolatrexed: Phase III data

...this indication, was licensed from Agouron Pharmaceuticals Inc. (La Jolla, Calif.), a subsidiary of PFE. Eximias Pharmaceutical Corp....
BioCentury | Aug 4, 2005
Clinical News

Eximias' Thymitaq fails HCC Phase III

Eximias (Berwyn, Penn.) said Thymitaq nolatrexed missed the primary endpoint of survival in the Phase III ETHECC trial to treat unresectable hepatocellular carcinoma (HCC). Data from the international, open-label trial in 446 patients were not...
BioCentury | Jul 4, 2005
Finance

Upcoming milestones

...Hypertension Submit MAA 3Q05 Epix/Schering Vasovist (MS-325) Cardiovascular imaging FDA response to NDA in November Eximias/Pfizer...
BioCentury | Jun 13, 2005
Company News

Eximias board of directors update

Eximias Pharmaceutical Corp. , Berwyn, Penn. Business: Cancer Appointed: Ruedi Waeger, former president and CEO of Aventis Behring LLC WIR Staff...
Items per page:
1 - 10 of 44